Clinical trial NCT00657176: An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors
Official title: A Phase 1, Open-Label, Non-Randomized Study of OPB-31121 in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Solid Tumor
Lead sponsor: Korea Otsuka Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2008-04-14
Enrollment: 36
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an open-label, non-randomized, single-center, dose-escalation study in patients with advanced solid tumors. Six dose levels (100, 200, 400, 600, 800, and 1000 mg/day) are planned for the study. In this study, OPB-31121's potential for toxic effects will be evaluated in patients with advanced solid tumors to evaluate the recommended dose for use in subsequent studies. The pharmacokinetics and antitumor effect of the compound will also be investigated.


Eligibility criteria: Inclusion Criteria

1. Histologically confirmed solid tumor refractory to standard therapy or for which there is no standard therapy
2. Age: more than 19 years
3. ECOG performance status: less than 2
4. Life expectancy of longer than 3 months
5. Adequate vital organ function as follows:

   * Bone marrow function

     * neutrophils: more than 1,500 per microliter
     * platelets: more than 75,000 per microliter
     * hemoglobin: more than 10.0g per deciliter
   * Hepatic function

     * AST and ALT: less than 2.5 x institutional upper limit normal
     * serum total bilirubin: less than 2.5 x institutional ULN
   * Renal function

     * Serum creatinine: less than 1.5 x institutional ULN
6. Capable of swallowing OPB-31121 tablets
7. Ability to understand and willingness to sign written informed consent document for participation in the trial and for analysis of genotypes CYP2C9 and NAT2
8. No chemotherapy, radiotherapy, surgery, or immunotherapy within 4 weeks prior to study entry and recovered from any prior toxicity

Exclusion criteria:

1. Symptomatic CNS metastasis
2. Uncontrolled concurrent illness, including active infection, heart failure, angina pectoris, and cardiac arrhythmia
3. Psychiatric illness that would limit compliance with study requirements
4. Pregnant or breast-feeding women and women of childbearing potential who cannot or will not use effective contraceptive measures
5. Administration of another investigational agent within 6 months prior to study entry
6. Use of CYP3A4 and CYP2C9 inducers, inhibitors, or substrates, and CYP2B6, CYP2C8 and CYP2D6 substrates
7. Hyperlipidemia:

   Total cholesterol:more than 300 milligram per deciliter or Triglycerides:

   more than 2.5 x institutional ULN
8. Abnormal thyroid function: Hypothyroidism or hyperthyroidism of grade 2 or higher (graded according to the NCI-CTCAE)

Primary outcomes:
measure: Maximum tolerated dose
timeFrame: Cycle 1
Secondary outcomes:
measure: Safety and dose-limiting toxicity
timeFrame: Duration of Study
measure: Pharmacokinetics
timeFrame: Cycle 1
measure: Antitumor effect
timeFrame: Duration of study
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Division of Hematology and Medical Oncology, Seoul National University Hospital
name: Yung-Jue Bang, PhD
role: PRINCIPAL_INVESTIGATOR
References: